These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34203711)

  • 1. Osteoclast-Mediated Cell Therapy as an Attempt to Treat Elastin Specific Vascular Calcification.
    Simpson CL; Mosier JA; Vyavahare NR
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34203711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The function and meaning of receptor activator of NF-κB ligand in arterial calcification.
    Nie B; Zhou SQ; Fang X; Zhang SY; Guan SM
    J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):666-671. PubMed ID: 26489619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of RANKL-induced osteoclastic differentiation by vascular cells.
    Tintut Y; Abedin M; Cho J; Choe A; Lim J; Demer LL
    J Mol Cell Cardiol; 2005 Aug; 39(2):389-93. PubMed ID: 15893766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human microvascular endothelial cell activation by IL-1 and TNF-alpha stimulates the adhesion and transendothelial migration of circulating human CD14+ monocytes that develop with RANKL into functional osteoclasts.
    Kindle L; Rothe L; Kriss M; Osdoby P; Collin-Osdoby P
    J Bone Miner Res; 2006 Feb; 21(2):193-206. PubMed ID: 16418775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway.
    Panizo S; Cardus A; Encinas M; Parisi E; Valcheva P; López-Ongil S; Coll B; Fernandez E; Valdivielso JM
    Circ Res; 2009 May; 104(9):1041-8. PubMed ID: 19325147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2003 Aug; 18(8):1404-18. PubMed ID: 12929930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The receptor activator of nuclear factor κΒ ligand receptor leucine-rich repeat-containing G-protein-coupled receptor 4 contributes to parathyroid hormone-induced vascular calcification.
    Carrillo-López N; Martínez-Arias L; Alonso-Montes C; Martín-Carro B; Martín-Vírgala J; Ruiz-Ortega M; Fernández-Martín JL; Dusso AS; Rodriguez-García M; Naves-Díaz M; Cannata-Andía JB; Panizo S
    Nephrol Dial Transplant; 2021 Mar; 36(4):618-631. PubMed ID: 33367746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
    Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
    Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligustilide suppresses RANKL-induced osteoclastogenesis and bone resorption via inhibition of RANK expression.
    Wang D; Li J; Feng W; Yao J; Ou L; Liao S; Liu Y; Li B; Lin C; Zhao J; Zhao G
    J Cell Biochem; 2019 Nov; 120(11):18667-18677. PubMed ID: 31436338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RANKL cytokine enhances TNF-induced osteoclastogenesis independently of TNF receptor associated factor (TRAF) 6 by degrading TRAF3 in osteoclast precursors.
    Yao Z; Lei W; Duan R; Li Y; Luo L; Boyce BF
    J Biol Chem; 2017 Jun; 292(24):10169-10179. PubMed ID: 28438834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of dimeric glucocorticoid receptors in osteoclast progenitors potentiates RANKL induced mature osteoclast bone resorbing activity.
    Conaway HH; Henning P; Lie A; Tuckermann J; Lerner UH
    Bone; 2016 Dec; 93():43-54. PubMed ID: 27596806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
    Michael H; Härkönen PL; Väänänen HK; Hentunen TA
    J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosines 559 and 807 in the cytoplasmic tail of the macrophage colony-stimulating factor receptor play distinct roles in osteoclast differentiation and function.
    Feng X; Takeshita S; Namba N; Wei S; Teitelbaum SL; Ross FP
    Endocrinology; 2002 Dec; 143(12):4868-74. PubMed ID: 12446614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
    Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N
    Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
    Collin-Osdoby P
    Circ Res; 2004 Nov; 95(11):1046-57. PubMed ID: 15564564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Alternative Macrophages Populate Calcified Areas of Atherosclerotic Lesions and Display Impaired RANKL-Induced Osteoclastic Bone Resorption Activity.
    Chinetti-Gbaguidi G; Daoudi M; Rosa M; Vinod M; Louvet L; Copin C; Fanchon M; Vanhoutte J; Derudas B; Belloy L; Haulon S; Zawadzki C; Susen S; Massy ZA; Eeckhoute J; Staels B
    Circ Res; 2017 Jun; 121(1):19-30. PubMed ID: 28438779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1.
    Sankar U; Patel K; Rosol TJ; Ostrowski MC
    J Bone Miner Res; 2004 Aug; 19(8):1339-48. PubMed ID: 15231022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage.
    Kobayashi Y; Ueyama S; Arai Y; Yoshida Y; Kaneda T; Sato T; Shin K; Kumegawa M; Hakeda Y
    J Bone Miner Metab; 2004; 22(4):318-28. PubMed ID: 15221489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.